NewAmsterdam Pharma Company N.V.NAMSNASDAQ
Loading
R&D Expenses Over TimeStrong
Percentile Rank60
3Y CAGR+17.8%
5Y CAGR+95.7%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
+17.8%/yr
Annual compound
5Y CAGR
+95.7%/yr
Recent deceleration
Percentile
P60
Within normal range
vs 5Y Ago
28.7x
Strong expansion
Streak
2 yr
Consecutive declineStrong
PeriodValueYoY Change
2025$141.83M-6.3%
2024$151.41M-5.0%
2023$159.42M+83.8%
2022$86.74M+199.4%
2021$28.97M+486.4%
2020$4.94M-